Stella, a US-based company involved in the delivery of high outcome treatments for emotional trauma and mental health management, announced on Wednesday that it has named Dr Pat Basu as the chairman of its board of directors.
Dr Basu is a veteran healthcare CEO, entrepreneur and former White House fellow. Presently, he serves as president and chief executive officer of Cancer Treatment Centers of America Global (CTCA). He is a business leader who has headed organisations in the public, private, non-profit and government sectors. He has managed organisations which collectively have delivered care or managed care for more than 25 million Americans per annum. He has served as a member of the Executive Leadership Team of UnitedHealth Group, president of OptumCare, partner-level positions at private equity firm Chicago Pacific Founders, operating partner of P3 Health Partners, and venture capital firm Pritzker Group Venture Capital. He has founded Doctor On Demand. He has served as a president, chief operating officer and chief medical officer at vRad. He serves on the board of directors for the Chicago Museum of Science and Industry and the Morton Arboretum. He has served as the founding faculty director of Health Policy and Finance at Stanford University. He has served on the Illinois State Board of Health, the Illinois Institute of Government & Public Affairs, Leadership Greater Chicago Daniel Burnham Fellow, the board of directors for the University of Illinois, and Stanford Medical Alumni Association, and has been a member of the Council on Foreign Relations.
Stella CEO, Philippe Sanchez, said, 'We are pleased that Dr Pat Basu has joined Stella's board, as our interests and mission have aligned to heal those experiencing devastating and lasting traumas of disease, cancer, and other life events. We hope to extend our network and make lasting impacts possible for those suffering.'
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories